Regentis Biomaterials Starts Q3 2026 European Surgeon Training for GelrinC
RGNT•Regentis Biomaterials will start European surgeon training in Q3 2026 for its CE Mark-approved GelrinC knee cartilage implant, beginning at Humanitas Research Hospital in Milan with sessions across Europe. The program, backed by a network of Centers of Excellence, offers hands-on experience with the cell-free implant.
1. Q3 2026 Surgeon Training Launch
Regentis Biomaterials will commence surgeon training for its CE Mark-approved GelrinC knee cartilage implant in the third quarter of 2026, starting at Humanitas Research Hospital in Milan. Additional sessions are scheduled across Europe to build hands-on proficiency among orthopedic surgeons.
2. Centers of Excellence Support
The training program is backed by a network of European Centers of Excellence that will provide clinical guidance, peer-to-peer knowledge sharing and ongoing surgeon education to facilitate broad adoption of the cell-free hydrogel implant.
3. GelrinC Product and Market Context
GelrinC is a ready-to-use, off-the-shelf hydrogel implant designed for single-step knee cartilage repair procedures. With approximately 470,000 annual U.S. cases lacking off-the-shelf options, the CE Mark approval paves the way for a substantial European commercial opportunity.
